Biolinq
San Diego, California, United States · Biotechnology, Health Care, Medical Device
Biolinq is a healthcare technology company pioneering precision multi-analyte wearable sensors to improve metabolic health. The company’s biosensor platform is designed to inform and inspire with unparalleled simplicity to support healthier living. With microsensors that reside just below the skin's surface, Biolinq is redefining the future of continuous small molecule biosensing.
Key facts
- Headquarters
- San Diego, California, United States
- Employees
- 107
- Industries
- Biotechnology, Health Care, Medical Device
- Status
- Private
- Website
- www.biolinq.com
- Company page
Recent activity at Biolinq
- : Biolinq secures $100M in Series C funding for its intradermal glucose sensor to improve metabolic health in type 2 diabetes, led by Alpha Wave Ventures.
- : Biolinq
- : Biolinq raised $58M in financing led by Alpha Wave Ventures for wearable biosensor tech and clinical trial on its glucose sensor
- : Biolinq
- : Biolinq
- : Biolinq
- : Biolinq Inc
- : Biolinq Inc
- : Biolinq Inc
- : Biolinq Inc
Dates are the day the event happened, taken from the announcement or SEC filing, unless a row says otherwise.
Biolinq funding history
| Date | Round | Amount |
|---|---|---|
| Apr 2025 | Series C | $100.0M |
| Mar 2025 | Venture | $90.0M |
| Apr 2024 | Funding Round | $58.0M |
| Dec 2023 | Venture | $35.1M |
| Sep 2021 | Venture | $62.2M |
Leadership
- Richard Yang, Executive Officer, Director
- Nancy Hong, Director
- Thad Johnson, Director
- Dan Bradbury, Director
- Jared Tangney, Executive Officer, Director, Promoter
- Lana Ghanem, Director
- Edward Kliphuis, Director
- Daniel Bradbury, Director
- Joshua Windmiller, Executive Officer, Director, Promoter
Verified email and direct lines for Biolinq’s decision-makers are on Fundz. See plans or book a 15-minute walkthrough.
Employee benefit plans
Biolinq files 2 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Biolinq in the news
- Can You Monitor Glucose Without A Needle Or A Prescription? FDA Clears A New Biosensor - Beyond Type 1 (Sep 30, 2026)
- Biolinq Shine Receives FDA De Novo Classification as First Multianalyte Wearable for Type 2 Diabetes - Pharmacy Times (Sep 26, 2025)
- Biolinq raises $100M for intradermal glucose sensor for type 2 diabetes - MobiHealthNews (Apr 22, 2025)
- Biolinq Shine Receives FDA Clearance as First Needle-Free Glucose Sensor - DSM - Diabetes Self-Management (Oct 03, 2025)
- Investors Put $58 Million Into Biolinq’s Push for Easier Glucose-Monitoring - WSJ (Apr 04, 2024)
- Biolinq Shine™ Granted De Novo Classification by U.S. FDA - GlobeNewswire (Sep 25, 2025)
- ADA25: Biolinq biosensor could track muscle loss during GLP-1 treatment - FirstWord Pharma (Jun 23, 2025)
- Biolinq Announces Close of $100M Series C Financing to Advance Its Biowearable Platform for Metabolic Health - Business Wire (Apr 22, 2025)
Companies similar to Biolinq
- Millar Holdings · Biotechnology, Health Care, Medical Device
- ZAP Surgical Systems · Biotechnology, Health Care, Medical Device
- Blue Earth Diagnostics · Biotechnology, Health Care, Medical Device
- KORU Medical Systems · Biotechnology, Health Care, Medical Device
- Medneo UK Limited · Biotechnology, Health Care, Medical Device
About Biolinq: questions and answers
What does Biolinq do?
Biolinq is a healthcare technology company pioneering precision multi-analyte wearable sensors to improve metabolic health. The company’s biosensor platform is designed to inform and inspire with unparalleled simplicity to support healthier living. With microsensors that reside just below the skin's surface, Biolinq is redefining the future of continuous small molecule biosensing.
Where is Biolinq headquartered?
Biolinq is headquartered in San Diego, California, United States.
How many employees does Biolinq have?
Biolinq has about 107 employees.
Has Biolinq raised funding?
Yes. Fundz has recorded 5 funding events for Biolinq. The most recent, Series C of $100.0M, was in Apr 2025.
What is the latest news on Biolinq?
On Apr 22, 2025, Biolinq secures $100M in Series C funding for its intradermal glucose sensor to improve metabolic health in type 2 diabetes, led by Alpha Wave Ventures.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy